Biological Role, Clinical Significance and Potential Therapeutic Applications of CD157 in Ovarian Cancer


  • S. Morone Laboratory of Immunogenetics, Department of Medical Sciences, University of Torino, Italy
  • N. Lo Buono Laboratory of Immunogenetics, Department of Medical Sciences, University of Torino, Italy
  • A. Giacomino Laboratory of Immunogenetics, Department of Medical Sciences, University of Torino, Italy
  • R. Parrotta Laboratory of Immunogenetics, Department of Medical Sciences, University of Torino, Italy
  • R. Arisio Città della Salute e della Scienza, Sant'Anna Hospital, Torino, Italy
  • D. Katsaros Città della Salute e della Scienza, Sant'Anna Hospital, Torino, Italy
  • N. Biglia Department of Oncological Gynecology, Umberto I Mauriziano Hospital, Torino, Italy
  • G. Chiorino Cancer Genomics Laboratory, Fondazione Edo ed Elvo Tempia Valenta, Biella, Italy
  • I. Rapa Department of Oncology, San Luigi Hospital, University of Torino, Torino, Italy
  • E. Ortolan Laboratory of Immunogenetics, Department of Medical Sciences, University of Torino, Italy
  • A. Funaro Laboratory of Immunogenetics, Department of Medical Sciences, University of Torino, Italy


Ovarian cancer, CD157, BST-1, tumor marker.


Ovarian cancer is the leading cause of gynecologic cancer-related morbidity and mortality owing to the difficulty in detecting early-stage disease. Despite advances in surgical and chemotherapeutic strategies, only marginal improvement in patient outcome has been achieved. Hence, understanding the biological mechanisms underlying ovarian cancer development and progression is critical for its treatment. We reported that CD157 (also known as BST-1), a NAD-metabolizing ectoenzyme regulating leukocyte diapedesis in inflammatory conditions, is expressed in approximately 90% of epithelial ovarian cancers and high CD157 expression is associated with poor outcome in patients. Our experimental results showed that CD157 controls ovarian cancer progression by promoting mesenchymal differentiation. The increased aggressiveness associated with tumors with high CD157 can be reverted in vitro by CD157 gene silencing, or by monoclonal antibodies that block CD157. The overall picture inferred from our experimental and clinical findings suggests that CD157 could aid diagnosis by classifying ovarian cancers into molecular subtypes with different outcomes, CD157 could also represent a novel candidate as a target of antibody-based therapies. This review summarizes and assesses recent research into the emerging functions of CD157 in the control of ovarian cancer progression..


Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010; 60(5): 277-300.

Coleman RL, Monk BJ, Sood AK, Herzog TJ. Latest research and treatment of advanced-stage epithelial ovarian cancer. Nat Rev Clin Oncol 2013; 10(4): 211-24.

Yigit R, Massuger LF, Figdor CG, Torensma R. Ovarian cancer creates a suppressive microenvironment to escape immune elimination. Gynecol Oncol 2010; 117(2): 366-72.

Feki A, Berardi P, Bellingan G, Major A, Krause KH, Petignat P, et al. Dissemination of intraperitoneal ovarian cancer: Discussion of mechanisms and demonstration of lymphatic spreading in ovarian cancer model. Crit Rev OncolHematol 2009; 72(1): 1-9.

Malayev Y, Levene R, Gonzalez F. Palliative chemotherapy for malignant ascites secondary to ovarian cancer. Am J Hosp Palliat Care 2012; 29(7): 515-21.

Lo Buono N, Morone S, Parrotta R, Giacomino A, Ortolan E, Funaro A. Ectoenzymes in epithelial ovarian carcinoma: potential diagnostic markers and therapeutic targets. In: Farghaly SA Ed. Ovarian Cancer – Basic science perspective. Rijeka, Croatia: InTech - Open Access Publisher 2011; pp. 245-70.

Seimetz D, Lindhofer H, Bokemeyer C. Development and approval of the trifunctional antibody catumaxomab (antiEpCAM x anti-CD3) as a targeted cancer immunotherapy. Cancer Treat Rev 2010; 36(6): 458-67.

Leone RMU, Bellati F, Ruscito I, Gasparri ML, Alessandri F, Venturini PL, et al. Monoclonal antibodies therapies for ovarian cancer. Expert Opin Biol Ther 2013; 13(5): 739-64.

Ferrero E, Malavasi F. Human CD38, a leukocyte receptor and ectoenzyme, is a member of a novel eukaryotic gene family of nicotinamide adenine dinucleotide+-converting enzymes: extensive structural homology with the genes for murine bone marrow stromal cell antigen 1 and aplysian ADP-ribosylcyclase. J Immunol 1997; 159(8): 3858-65.

Malavasi F, Deaglio S, Funaro A, Ferrero E, Horenstein AL, Ortolan E, et al. Evolution and function of the ADP ribosylcyclase/CD38 gene family in physiology and pathology. Physiol Rev 2008; 88(3): 841-86.

Galione A, Chuang KT. Pyridine nucleotide metabolites and calcium release from intracellular stores. Adv Exp Med Biol 2012; 740: 305-23.

Ishihara K, Hirano T. BST-1/CD157 regulates the humoral immune responses in vivo. Chem Immunol 2000; 75: 235-55.

Lavagno L, Ferrero E, Ortolan E, Malavasi F, Funaro A. CD157 is part of a supramolecular complex with CD11b/CD18 on the human neutrophil cell surface. J Biol Regul Homeost Agents 2007; 21(1-2): 5-11.

Lo Buono N, Parrotta R, Morone S, Bovino P, Nacci G, Ortolan E, et al. The CD157-integrin partnership controls transendothelial migration and adhesion of human monocytes. J Biol Chem 2011; 286(21): 18681-91.

Kaisho T, Ishikawa J, Oritani K, Inazawa J, Tomizawa H, Muraoka O, et al. BST-1, a surface molecule of bone marrow stromal cell lines that facilitates pre-B-cell growth. Proc Natl Acad Sci USA 1994; 91(12): 5325-29.

Goldstein SC, Todd RF, 3rd. Structural and biosynthetic features of the Mo5 human myeloid differentiation antigen. Tissue Antigens 1993; 41(4): 214-8.

Funaro A, Ortolan E, Ferranti B, Gargiulo L, Notaro R, Luzzatto L, et al. CD157 is an important mediator of neutrophil adhesion and migration. Blood 2004; 104(13): 4269-78.

Ortolan E, Tibaldi EV, Ferranti B, Lavagno L, Garbarino G, Notaro R. et al. CD157 plays a pivotal role in neutrophil transendothelial migration. Blood 2006; 108(13): 4214-22.

Ortolan E, Vacca P, Capobianco A, Armando E, Crivellin F, Horenstein A, et al. CD157, the Janus of CD38 but with a unique personality. Cell Biochem Funct 2002; 20(4): 309-22.

Quarona V, Zaccarello G, Chillemi A, Brunetti E, Singh VK, Ferrero E, et al. CD38 and CD157: A long journey from activation markers to multifunctional molecules. Cytometry B 2013; in press.

Ortolan E, Arisio R, Morone S, Bovino P, Lo-Buono N, Nacci G, et al. Functional Role and Prognostic Significance of CD157 in Ovarian Carcinoma. J Natl Cancer Inst 2010; 105(16): 1160-77.

Morone S, Lo Buono N, Parrotta R, Giacomino A, Nacci G, Brusco A, et al. Overexpression of CD157 contributes to epithelial ovarian cancer progression by promoting mesenchymal differentiation. PLoS ONE 2012; 7(8): e43649.

Chaffer CL, Weinberg RA. A perspective on cancer cell metastasis. Science 2011; 331(6024): 1559-64.

De Craene B, Berx G. Regulatory networks defining EMT during cancer initiation and progression. Nat Rev Cancer 2013; 13(2): 97-110.

Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou AY, et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 2008; 133(4): 704-15.

Scheel C, Weinberg RA. Cancer stem cells and epithelialmesenchymal transition: concepts and molecular links. Semin Cancer Biol 2012; 22(5-6): 396-403.

Munz M, Baeuerle PA, Gires O. The emerging role of EpCAM in cancer and stem cell signaling. Cancer Res 2009; 69(14): 5627-29.

Gao MQ, Choi YP, Kang S, Youn JH, Cho NH. CD24+ cells from hierarchically organized ovarian cancer are enriched in cancer stem cells. Oncogene 2010; 29(10): 2672-80.

Visvader JE, Lindeman GJ. Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat Rev Cancer 2008; 8: 755-68.

Funaro A, Ortolan E, Bovino P, Lo Buono N, Nacci G, Parrotta R, et al. Ectoenzymes and innate immunity: The role of human CD157 in leukocyte trafficking. Frontiers in Bioscience 2009; 14: 929-43.

Ross JA, Ansell I, Hjelle JT, Anderson JD, Miller-Hjelle MA, Dobbie JW. Phenotypic mapping of human mesothelial cells. Adv Perit Dial 1998; 14: 25-30.

Sessa C, Del Conte G. Targeted therapies: tailored treatment for ovarian cancer: are we there yet? Nat Rev Clin Oncol 2010; 7(2): 80-2.